# FDA Clears IND for ATR-1072 RNA Cardiac Therapy in PRKAG2 Syndrome

> fda · REPORTED · 2026-07-14

Atrium Therapeutics (Nasdaq: RNA) announced on July 14, 2026 that the FDA cleared its IND application for ATR-1072, allowing the company to advance its first precision cardiology RNA therapeutic into the clinic for the treatment of PRKAG2 syndrome, a rare genetic cardiomyopathy.

About Atrium Therapeutics: Atrium Therapeutics is a biopharmaceutical company pioneering targeted RNA (siRNA) therapeutics delivered selectively to the heart using antibody-conjugate technology to treat genetically driven cardiomyopathies.

- Company: Atrium Therapeutics
- Sector: cardiology
- Primary source: https://www.sec.gov/Archives/edgar/data/0002093101/000119312526303393/d132402dex991.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.